Loading
A phase 2 trial of Acalabrutinib, Venetoclax, Rituximab in mantle cell lymphoma, run by AstraZeneca, active and no longer recruiting.
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05951959 by AstraZeneca, with 108 participants enrolled, started 2023-12-13 and due to reach its primary completion in 2028-10-31. Interventions recorded: Acalabrutinib, Venetoclax, Rituximab. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, Rituximab, Mantle cell lymphoma, AstraZeneca.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, AstraZeneca.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, AstraZeneca.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, Monoclonal antibodies.
Shares BCL-2 inhibitors, Venetoclax, Rituximab, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/